Trials / Completed
CompletedNCT02711956
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Zenith Epigenetics · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZEN003694 | |
| DRUG | Enzalutamide |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-11-01
- Completion
- 2019-11-01
- First posted
- 2016-03-17
- Last updated
- 2021-11-30
- Results posted
- 2021-08-10
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02711956. Inclusion in this directory is not an endorsement.